Author: admin

Affordable & Professional Window & Gutter Cleaning Powerwashing Services Delivers Superior Exterior Cleaning Solutions in Freehold, NJ

Affordable & Professional Window & Gutter Cleaning Powerwashing Services Delivers Superior Exterior Cleaning Solutions in Freehold, NJ
Affordable & Professional Window & Gutter Cleaning Powerwashing Services continues to set the standard for exceptional exterior cleaning services in the region. With a reputation built on reliability and attention to detail, the company offers comprehensive solutions for both residential and commercial properties throughout Monmouth County and beyond.

Known for expert pressure washing and meticulous care of all exterior surfaces, Affordable & Professional Window & Gutter Cleaning Powerwashing Services specializes in transforming properties through advanced cleaning techniques. Homeowners and business owners seeking Freehold Pressure Washing services can rely on this locally trusted provider for spotless and lasting results.

The company’s technicians use top-grade equipment and eco-friendly products to ensure effective cleaning that enhances curb appeal while preserving property value. Services include siding, concrete, patios, decks, driveways, and roof cleaning. Those looking for Pressure Washing Freehold services benefit from a well-trained team that understands the specific challenges of the local environment, including mold, mildew, and seasonal debris.

With a commitment to customer satisfaction and high-quality workmanship, Affordable & Professional Window & Gutter Cleaning Powerwashing Services has become the go-to choice forPressure Washing in Freehold. The company also offers specialized services such as window cleaning, gutter maintenance, and soft washing for delicate surfaces, ensuring comprehensive care for every property.

Serving the Freehold community with pride and professionalism, Affordable & Professional Window & Gutter Cleaning Powerwashing Services invites property managers, real estate professionals, and homeowners to discover the difference that true exterior cleaning expertise can make.

Media Contact
Company Name: Affordable & Professional Window & Gutter Cleaning Powerwashing Services
Contact Person: John Oshinski
Email: Send Email
Phone: (732) 462-0462
Address:18 Willow Brook Rd
City: Freehold
State: NJ 07728
Country: United States
Website: https://www.affordable-and-professional.com/

Desert Kids Dental Continues to Provide HealthyStart® Program for Long-Term Pediatric Wellness in Las Vegas

“Dr. Sandra Thompson at Desert Kids Dental in Las Vegas, NV.”
Desert Kids Dental, a trusted kids dentist serving Las Vegas communities has long offered the HealthyStart® program to support children’s oral development and overall health.

Desert Kids Dental, a trusted kids dentist serving Las Vegas communities including Providence, Skye Canyon, Summerlin, and Centennial Hills, has long offered the HealthyStart® program to support children’s oral development and overall health. Under the experienced care of Dr. Sandra Thompson, this non-invasive treatment continues to help children achieve better sleep, healthier airways, and properly aligned smiles—all without braces or surgery.

What Is the HealthyStart® Program?

The HealthyStart® system is a series of soft, comfortable oral appliances designed to address sleep-disordered breathing (SDB) in children. Worn primarily at night, the appliance gently guides the growth of the jaws, expands the airway, and aligns teeth as they develop. This early intervention can prevent the need for future orthodontic treatment while also improving sleep and behavior.

Dr. Sandra Thompson and her team have successfully used HealthyStart® to support children struggling with mouth breathing, snoring, grinding, bedwetting, or signs of ADHD—all of which are often linked to undiagnosed sleep issues. By identifying these concerns early, Desert Kids Dental provides families with effective tools to promote both oral health and overall well-being.

Why Families in Las Vegas Choose HealthyStart®

  • Non-Invasive & Drug-Free: No surgery or medications—just gentle guidance through custom-fit oral appliances.
  • Better Sleep = Better Behavior: Improved breathing at night can lead to better focus, mood, and learning during the day.
  • Supports Natural Tooth Alignment: Guides teeth into their ideal position during growth, often eliminating the need for braces.
  • Addresses the Root Cause: Focuses on airway development and jaw positioning, not just symptoms.


Leading Care from a Dedicated Kids Dentist

Dr. Sandra Thompson is known throughout Las Vegas as a compassionate, knowledgeable kids dentist who focuses on preventive care and whole-child wellness. Her commitment to offering advanced solutions like HealthyStart® reflects the clinic’s broader mission—to give every child the healthiest start possible.

At Desert Kids Dental, families find a supportive environment where concerns are heard, children feel safe, and early intervention is always the goal. Whether it’s a routine checkup or a comprehensive evaluation for airway health, Dr. Thompson ensures each treatment plan is tailored to the child’s needs.

Serving Providence, Skye Canyon, Summerlin, and Centennial Hills

Located conveniently in Northwest Las Vegas, Desert Kids Dental continues to be a trusted choice for families across Providence, Skye Canyon, Summerlin, and Centennial Hills. Parents looking for a reliable kids dentist who offers innovative, child-friendly solutions find peace of mind knowing their child’s growth and development are supported at every stage.

Desert Kids Dental also offers a wide range of pediatric dental services—from cleanings and fluoride treatments to sealants and restorative care. The integration of the HealthyStart® program reflects the clinic’s belief in treating the root causes of dental and developmental concerns, not just the symptoms.

Book Your Child’s HealthyStart® Evaluation

If your child shows signs of restless sleep, difficulty breathing at night, or crowded teeth, it may be time to schedule a consultation. Desert Kids Dental offers comprehensive evaluations to determine if the HealthyStart® program is right for your child.

For families searching for a trusted kids dentist in Las Vegas, Desert Kids Dental remains a leading provider of expert pediatric care and early developmental support.

Media Contact
Company Name: Desert Kids Dental
Contact Person: Media Relations
Email: Send Email
Phone: 702-660-7099
Address:9859 W Deer Springs Way STE 110
City: Las Vegas
State: NV 89149
Country: United States
Website: https://www.desertkidsdental.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Desert Kids Dental Continues to Provide HealthyStart® Program for Long-Term Pediatric Wellness in Las Vegas

PAWPANG Launches Upgraded Dog Diaper Liners with Enhanced Absorbency and Leak-Proof Fit

PAWPANG, the premium pet hygiene brand known for its leak-proof dog diaper liners, has announced a major product upgrade following a full brand refresh. The new and improved booster pads for dogs are now available, featuring enhanced absorbency, better fit, and a cleaner, more premium brand experience.

Upgraded Absorbency with Japanese Core Materials

The biggest innovation? Each liner now absorbs 1–2 fl oz more liquid per size, thanks to an advanced Japanese-made absorbent core. Designed for use with reusable dog diapers, male wraps, and female dog diapers, the liners instantly lock in urine and help keep your home dry. No more unexpected leaks on your floors, furniture, or bedding.

Secure Fit, Even for Active Dogs

PAWPANG also upgraded its adhesive system, going from 4 to 5 adhesive strips, improving the stay-put grip even for wiggly, playful pups. Whether you’re using them with belly bands or full-coverage reusable diapers, the liners now offer better performance with less shifting and bunching.

Smarter Embossing, Cleaner Branding

In addition to performance, PAWPANG’s new liners now feature a custom-designed signature embossing pattern, replacing the generic texture seen in most brands. The new embossing ensures better fluid distribution while visually reinforcing the brand’s premium identity.

To match this evolution, PAWPANG also revealed a full brand redesign, including new packaging, a refreshed brand mascot, and color-coded size indicators for easier selection.

Quick Summary of What’s New:

  • +1–2 fl oz more absorbency per liner (by size)
  • Upgraded from 4 to 5 adhesive strips for better fit
  • New signature PAWPANG embossing pattern for leak control
  • Complete brand refresh: packaging, character, and tone

Designed for Real-Life Messes

Perfect for senior dogs, UTI (Urinary Tract Infection), incontinence, dogs in heat, indoor markers, or mobility issue, PAWPANG dog diaper booster pads work seamlessly with reusable and disposable dog diapers. They’re also a popular insert for male belly bands, helping pet parents reduce full diaper changes, lower laundry loads, and improve everyday hygiene.

“It’s the small improvements that make the biggest difference,” says the PAWPANG team. “We listened to what our customers were saying especially about absorption and adhesive performance. Hence, we upgraded exactly where it mattered most, without changing what they already loved.”

The new liners are now available on Amazon and PAWPANG brand website.

Media Contact
Company Name: PAWPANG
Contact Person: Theo Lee
Email: Send Email
Country: Korea
Website: https://www.pawpang.com/

Advanced Cancer Pain Management Pipeline Appears Robust With 3+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Advanced Cancer Pain Management (ACPM) Pipeline Insight 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Advanced Cancer Pain Management (ACPM) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Advanced Cancer Pain Management Pipeline. Dive into DelveInsight’s comprehensive report today! @ Advanced Cancer Pain Management Pipeline Outlook

Key Takeaways from the Advanced Cancer Pain Management Pipeline Report

  • DelveInsight’s Advanced Cancer Pain Management Pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Advanced Cancer Pain Management treatment.
  • The leading Advanced Cancer Pain Management Companies such as Tetra Bio-Pharma, ZYUS Life Sciences, and others.
  • Promising Advanced Cancer Pain Management Pipeline Therapies such as Sativex Low Dose, Nabiximols, GA-0034, and others.

Stay ahead with the most recent pipeline outlook for Advanced Cancer Pain Management. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Advanced Cancer Pain Management Treatment Drugs

Advanced Cancer Pain Management Emerging Drugs Profile

  • QIXLEEF: Tetra Bio-Pharma

QIXLEEF is a cannabinoid-derived medicines developed by Tetra Bio-pharma for the treatment of uncontrolled pain in advanced cancer patients. It is a first-generation, cannabinoid receptor agonists and is derived from a dried cannabis flower bud. QIXLEEF contains no excipients or other nonmedicinal ingredients. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients suffering from advanced cancer pain management.

The Advanced Cancer Pain Management Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Cancer Pain Management with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Cancer Pain Management Treatment.
  • Advanced Cancer Pain Management Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Advanced Cancer Pain Management Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Cancer Pain Management market

Explore groundbreaking therapies and clinical trials in the Advanced Cancer Pain Management Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Advanced Cancer Pain Management Drugs

Advanced Cancer Pain Management Companies

Tetra Bio-Pharma, ZYUS Life Sciences, and others.

Advanced Cancer Pain Management (ACPM) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

Advanced Cancer Pain Management Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

Unveil the future of Advanced Cancer Pain Management Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Advanced Cancer Pain Management Market Drivers and Barriers

Scope of the Advanced Cancer Pain Management Pipeline Report

  • Coverage- Global
  • Advanced Cancer Pain Management Companies- Tetra Bio-Pharma, ZYUS Life Sciences, and others.
  • Advanced Cancer Pain Management Pipeline Therapies- Sativex Low Dose, Nabiximols, GA-0034, and others.
  • Advanced Cancer Pain Management Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Advanced Cancer Pain Management Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Advanced Cancer Pain Management Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Advanced Cancer Pain Management Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Advanced Cancer Pain Management: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced Cancer Pain Management– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name: Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. QIXLEEF: Tetra Bio-Pharma
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug name: Company name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Advanced Cancer Pain Management Key Companies
  21. Advanced Cancer Pain Management Key Products
  22. Advanced Cancer Pain Management- Unmet Needs
  23. Advanced Cancer Pain Management- Market Drivers and Barriers
  24. Advanced Cancer Pain Management- Future Perspectives and Conclusion
  25. Advanced Cancer Pain Management Analyst Views
  26. Advanced Cancer Pain Management Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/advanced-cancer-pain-management-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Cancer Pain Management Pipeline Appears Robust With 3+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

NSCLC Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Non-Small-Cell Lung cancer (NSCLC) Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NSCLC Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the NSCLC Pipeline. Dive into DelveInsight’s comprehensive report today! @ NSCLC Pipeline Outlook

Key Takeaways from the NSCLC Pipeline Report

  • In May 2025, Suzhou Junjing BioSciences Co., Ltd. announced a Phase II clinical study evaluating JS111 capsules (AP-L1898) as monotherapy in patients with advanced NSCLC harboring EGFR mutations.Approximately 3 to 42 treatment-naïve patients with EGFR mutation-positive locally advanced, metastatic, or recurrent NSCLC will be enrolled.Based on prior safety, PK, and efficacy data, two dose levels-160 mg QD and 240 mg QD-will be tested to assess safety, tolerability, PK, and preliminary efficacy, and to determine the recommended Phase II dose (RP2D), as referenced in Section 4.3.
  • In May 2025, AstraZeneca conducted a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.
  • In May 2025, Revolution Medicines Inc. organized a Phase 3 study designed to evaluate whether treatment with daraxonrasib will improve progression free survival (PFS) or overall survival (OS) compared to docetaxel chemotherapy in patients with NSCLC who were previously treated. Patients will be randomized in a 1:1 ratio to receive daraxonrasib or docetaxel chemotherapy.
  • In May 2025, Amgen announced a study is to characterize safety and efficacy of 2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR).
  • DelveInsight’s NSCLC Pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for NSCLC treatment.
  • The leading NSCLC Companies such as GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Sanofi, IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, and TYK Medicines Inc. and others.
  • Promising NSCLC Pipeline Therapies such as Brigatinib, Tyrosine kinase inhibitor, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab, and others.

Stay ahead with the most recent pipeline outlook for NSCLC. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ NSCLC Treatment Drugs

NSCLC Emerging Drugs Profile

  • AMG 510: Amgen

AMG 510 is being developed by Amgen. Phase 1 clinical trials were completed in late 2020. Because the G12C KRAS mutation is relatively common in some cancer types, 14% of non-small-cell lung cancer adenocancer patients and 5% of colorectal cancer patients, and AMG 510 is the first drug candidate to target this mutation, there have been high expectations for the drug. The Food and Drug Administration has granted a fast track designation to AMG 510 for the treatment of metastatic non-small-cell lung cancer with the G12C KRAS mutation. The drug is in preregistration stage for the treatment of NSCLC.

  • CMP 001: Cytos Biotechnology

CMP 001 is a short piece of DNA, called an oligonucleotide that Checkmate designed to mimic the DNA of bacteria. It encapsulated the DNA in noninfectious virus-like particles, or VLPs. The company created CMP-001 to be administered directly to a tumor. When this occurs, the immune system sees VLPs as foreign. It generates immune cells called antigen presenting cells that release the DNA from the VLPs. CMP 001 is in phase 1 of clinical trials for the treatment of non-small cell lung cancer.

NSCLC.

The NSCLC Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of NSCLC with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NSCLC Treatment.
  • NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NSCLC market

Explore groundbreaking therapies and clinical trials in the NSCLC Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New NSCLC Drugs

NSCLC Companies

GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Sanofi, IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, and TYK Medicines Inc. and others.

Non-Small-Cell Lung cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Oral
  • Parenteral
  • Intramuscular
  • Molecule Type

NSCLC Products have been categorized under various Molecule types such as

  • Small molecules
  • Peptides
  • Polymer
  • Gene Therapy
  • Monoclonal antibodies
  • Product Type

Unveil the future of NSCLC Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ NSCLC Market Drivers and Barriers

Scope of the NSCLC Pipeline Report

  • Coverage- Global
  • NSCLC Companies- GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Sanofi, IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, and TYK Medicines Inc. and others.
  • NSCLC Pipeline Therapies- Brigatinib, Tyrosine kinase inhibitor, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab, and others.
  • NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on NSCLC Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ NSCLC Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Non-Small-Cell Lung cancer (NSCLC): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Non-Small-Cell Lung cancer (NSCLC) – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Late Stage Products (Pre Registration)
  9. AMG 510: Amgen
  10. Drug profiles in the detailed report…..
  11. Mid Stage Products (Phase II)
  12. Drug Name: Company Name
  13. Drug profiles in the detailed report…..
  14. Early Stage Products (Phase I)
  15. CMP 001: Cytos Biotechnology
  16. Drug profiles in the detailed report…..
  17. Inactive Products
  18. Non-Small-Cell Lung cancer (NSCLC) Key Companies
  19. Non-Small-Cell Lung cancer (NSCLC) Key Products
  20. Non-Small-Cell Lung cancer (NSCLC)- Unmet Needs
  21. Non-Small-Cell Lung cancer (NSCLC)- Market Drivers and Barriers
  22. Non-Small-Cell Lung cancer (NSCLC)- Future Perspectives and Conclusion
  23. Non-Small-Cell Lung cancer (NSCLC) Analyst Views
  24. Non-Small-Cell Lung cancer (NSCLC) Key Companies
  25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: NSCLC Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Meningioma Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Meningioma Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Meningioma pipeline landscape. It covers the Meningioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Meningioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Meningioma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Meningioma Pipeline Outlook

Key Takeaways from the Meningioma Pipeline Report

  • In May 2025, European Organisation for Research and Treatment of Cancer – EORTC conducted a LUMEN-1 trial will investigate in a prospective randomized trial the efficacy of the precision medicine “theranostic” concept of combining diagnostic patient selection using PET-based molecular imaging and target-specific therapeutic intervention using a systemically administered radioligand.
  • In May 2025, Baptist Health South Florida announced a phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma.
  • DelveInsight’s Meningioma Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Meningioma treatment.
  • The leading Meningioma Companies such as NX Development Corp., Clarity Pharmaceutical Ltd., Bristol-Myers Squibb, Biosynthema Inc., and others.
  • Promising Meningioma Pipeline Therapies such as Nivolumab, Cabozantinib, Abemaciclib, SOM230C, Bevacizumab, 177Lu-DOTATATE, Pembrolizumab and others.

Stay ahead with the most recent pipeline outlook for Meningioma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Meningioma Treatment Drugs

Meningioma Emerging Drugs Profile

  • Gleolan: NX Devolopment Corp

NX development corp.’s drug, Gleolan also known as Aminolevulinic acid is an orally administered small molecule in development for the treatment and real time detection of meningioma. Gleolan is a prodrug that is metabolized intracellularly to form the fluorescent molecule Protoporphyrin IX (PpIX). The exogenous application of ALA leads to a highly selective accumulation of PpIX in tumor cells. Following excitation with blue light. It is a photosensitizer molecule which can utilize the energy to induce photochemical reactions to produce lethal toxic agents; ultimately results in cell death and tissue destruction.

  • Nivolumab: Bristol-Myers Squibb

Bristol-Myers Squibb “breakthrough” drug nivolumab is currently being evaluated for the treatment of Meningioma and has demonstrated good safety and efficacy profile in phase II trials. Nivolumab is a human immunoglobin (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks the interaction with PD-L1 and PD-L2, releasing anti-tumor response.

The Meningioma Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Meningioma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Meningioma Treatment.
  • Meningioma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Meningioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Meningioma market

Explore groundbreaking therapies and clinical trials in the Meningioma Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Meningioma Drugs

Meningioma Companies

NX Development Corp., Clarity Pharmaceutical Ltd., Bristol-Myers Squibb, Biosynthema Inc., and others.

Meningioma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type

Meningioma Products have been categorized under various Molecule types such as

  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type

Unveil the future of Meningioma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Meningioma Market Drivers and Barriers

Scope of the Meningioma Pipeline Report

  • Coverage- Global
  • Meningioma Companies- NX Development Corp., Clarity Pharmaceutical Ltd., Bristol-Myers Squibb, Biosynthema Inc., and others.
  • Meningioma Pipeline Therapies- Nivolumab, Cabozantinib, Abemaciclib, SOM230C, Bevacizumab, 177Lu-DOTATATE, Pembrolizumab and others.
  • Meningioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Meningioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Meningioma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Meningioma Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Meningioma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Meningioma – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Meningioma Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Gleolan: Nx Development Corp.
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. Nivolumab: Bristol-Myers Squibb
  14. Drug profiles in the detailed report…..
  15. Pre-clinical and Discovery Stage Products
  16. Drug profiles in the detailed report…..
  17. Inactive Products
  18. Meningioma Key Companies
  19. Meningioma Key Products
  20. Meningioma- Unmet Needs
  21. Meningioma- Market Drivers and Barriers
  22. Meningioma- Future Perspectives and Conclusion
  23. Meningioma Analyst Views
  24. Meningioma Key Companies
  25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/meningioma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Meningioma Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Uterine Leiomyosarcoma Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Uterine Leiomyosarcoma Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Uterine Leiomyosarcoma pipeline landscape. It covers the Uterine Leiomyosarcoma Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Uterine Leiomyosarcoma Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Uterine Leiomyosarcoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Uterine Leiomyosarcoma Pipeline Outlook

Key Takeaways from the Uterine Leiomyosarcoma Pipeline Report

  • In March 2025, UNICANCER announced a phase II trial designed to demonstrate whether adding 4 cycles of post-operative chemotherapy improves relapse-free survival as compared with follow-up (standard management) in patients with resected FIGO stage I uterine leiomyosarcoma, considered at high-risk according to CINSARC NanoCind® signature.
  • DelveInsight’s Uterine Leiomyosarcoma Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Uterine Leiomyosarcoma treatment.
  • The leading Uterine Leiomyosarcoma Companies such as Novartis, PharmMar, and others.
  • Promising Uterine Leiomyosarcoma Pipeline Therapies such as Doxorubicin, Trabectedin, gemcitabine + docetaxel, letrozole, Pazopanib, Carboplatin and others.

Stay ahead with the most recent pipeline outlook for Uterine Leiomyosarcoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Uterine Leiomyosarcoma Treatment Drugs

Uterine Leiomyosarcoma Emerging Drugs Profile

  • Trabectedin: PharmMar

Yondelis® (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from Ecteinascidia turbinata, a type of sea squirt. Yondelis® exerts its anticancer effects primarily by inhibiting active transcription, a type of gene expression on which proliferating cancer cells are particularly dependent.

  • Letrozole: Novartis

Letrozole is a non-steroidal type II aromatase inhibitor. It blocks the active site, and therefore the electron transfer chain of CYP19A1. This competitive inhibition prevents the conversion of androgens to estrogen. This action leads to a reduction in uterine weight and elevated leuteinizing hormone.8 In postmenopausal women, the action of aromatase is responsible for the majority of estrogen production. With reduced availability of estrogen, estrogen-dependant tumors regress. Third generation aromatase inhibitors do not significantly affect cortisol, aldosterone, and thyroxine levels. Currently, in phase II of clinical trials.

The Uterine Leiomyosarcoma Pipeline Report Provides Insights into

 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Uterine Leiomyosarcoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Uterine Leiomyosarcoma Treatment.
  • Uterine Leiomyosarcoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Uterine Leiomyosarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Uterine Leiomyosarcoma market

Explore groundbreaking therapies and clinical trials in the Uterine Leiomyosarcoma Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Uterine Leiomyosarcoma Drugs

Uterine Leiomyosarcoma Companies

Novartis, PharmMar, and others.

Uterine Leiomyosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type

Uterine Leiomyosarcoma Products have been categorized under various Molecule types such as

  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type

Unveil the future of Uterine Leiomyosarcoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Uterine Leiomyosarcoma Market Drivers and Barriers

Scope of the Uterine Leiomyosarcoma Pipeline Report

  • Coverage- Global
  • Uterine Leiomyosarcoma Companies- Novartis, PharmMar, and others.
  • Uterine Leiomyosarcoma Pipeline Therapies- Doxorubicin, Trabectedin, gemcitabine + docetaxel, letrozole, Pazopanib, Carboplatin and others.
  • Uterine Leiomyosarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Uterine Leiomyosarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Uterine Leiomyosarcoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Uterine Leiomyosarcoma Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Uterine Leiomyosarcoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Uterine Leiomyosarcoma – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Uterine Leiomyosarcoma Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Drug profiles in the detailed report…..
  11. Mid Stage Products (Phase II)
  12. Letrozole: Novartis
  13. Drug profiles in the detailed report…..
  14. Pre-clinical and Discovery Stage Products
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. Uterine Leiomyosarcoma Key Companies
  18. Uterine Leiomyosarcoma Key Products
  19. Uterine Leiomyosarcoma- Unmet Needs
  20. Uterine Leiomyosarcoma- Market Drivers and Barriers
  21. Uterine Leiomyosarcoma- Future Perspectives and Conclusion
  22. Uterine Leiomyosarcoma Analyst Views
  23. Uterine Leiomyosarcoma Key Companies
  24. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/uterine-leiomyosarcoma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Uterine Leiomyosarcoma Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Central Nervous System Tumors Pipeline Appears Robust With 13+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s “Central Nervous System Tumors Pipeline Insight 2025” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Central Nervous System Tumors pipeline landscape. It covers the Central Nervous System Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Central Nervous System Tumors Pipeline. Dive into DelveInsight’s comprehensive report today! @ Central Nervous System Tumors Pipeline Outlook

Key Takeaways from the Central Nervous System Tumors Pipeline Report

  • In May 2025, Genmab announced a study will be conducted in two parts: Part 1 (dose-finding) and Part 2 (randomization). The main purpose is to assess the safety and clinical activity of GEN1042 in combination with radiotherapy or GEN1042 in combination with radiotherapy and pembrolizumab as a treatment option for participants with metastatic solid tumors.
  • In May 2025, Stemline Therapeutics Inc. announced a study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was designed to select the recommended phase 2 dose and is followed by an ongoing phase 2 evaluation of elacestrant in combination with abemaciclib in patients with active brain metastases from ER-positive, HER-2 negative breast cancer.
  • In May 2025, Hoffmann-La Roche organized a study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.
  • DelveInsight’s Central Nervous System Tumors Pipeline report depicts a robust space with 13+ active players working to develop 13+ pipeline therapies for Central Nervous System Tumors treatment.
  • Promising Central Nervous System Tumors Companies such as Shandong New Time Pharmaceutical, PIQUR Therapeutics, Ono Pharmaceutical, Janssen, LP, Kazia Therapeutics, Beijing InnoCare Pharma Tech, Celltrion, Bristol Myers Squibb, AstraZeneca, Novartis, Prelude Therapeutics, Kite, A Gilead Company, Celgene and others.
  • The leading Central Nervous System Tumors Pipeline Therapies such as Tozuleristide, Bevacizumab, Temozolomide, Pomalidomide, Niraparib, GNC-038, Pamiparib, Thalidomide and others.

Stay ahead with the most recent pipeline outlook for Central Nervous System Tumors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Central Nervous System Tumors Treatment Drugs

Central Nervous System Tumors Emerging Drugs Profile

  • F520: Shandong New Time Pharmaceutical

F 520 is a humanized monoclonal antibody targeting programmed cell death 1 receptor antagonists being developed by Shandong New Time Pharmaceutical. The drug is being investigated in Phase II stage of development for the treatment of patients with Primary and secondary Central Nervous System Lymphoma.

  • Tirabrutinib: Ono Pharmaceuticals

Velexbru, discovered and developed by ONO, is a highly selective, oral BTK inhibitor and has been developed for the treatment in patients with B-cell tumors and autoimmune diseases in Japan. B-cell receptor (BCR) signaling plays a core role in the survival, activation, proliferation, maturation and differentiation of B-cell lymphocyte. In Japan, Velexbru was approved in March 2020 and launched in May 2020 for the treatment of relapsed or refractory primary central nervous system lymphoma (PCNSL). Ono Pharmaceutical has initiated a Phase II clinical trial in US with Velexbru in patients with primary central nervous system lymphoma.

The Central Nervous System Tumors Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Central Nervous System Tumors with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Central Nervous System Tumors Treatment.
  • Central Nervous System Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Central Nervous System Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Central Nervous System Tumors market

Explore groundbreaking therapies and clinical trials in the Central Nervous System Tumors Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Central Nervous System Tumors Drugs

Central Nervous System Tumors Companies

Shandong New Time Pharmaceutical, PIQUR Therapeutics, Ono Pharmaceutical, Janssen, LP, Kazia Therapeutics, Beijing InnoCare Pharma Tech, Celltrion, Bristol Myers Squibb, AstraZeneca, Novartis, Prelude Therapeutics, Kite, A Gilead Company, Celgene and others.

Central Nervous System Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
  • Molecule Type

Central Nervous System Tumors Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Unveil the future of Central Nervous System Tumors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Central Nervous System Tumors Market Drivers and Barriers

Scope of the Central Nervous System Tumors Pipeline Report

  • Coverage- Global
  • Central Nervous System Tumors Companies- Shandong New Time Pharmaceutical, PIQUR Therapeutics, Ono Pharmaceutical, Janssen, LP, Kazia Therapeutics, Beijing InnoCare Pharma Tech, Celltrion, Bristol Myers Squibb, AstraZeneca, Novartis, Prelude Therapeutics, Kite, A Gilead Company, Celgene and others.
  • Central Nervous System Tumors Pipeline Therapies- Tozuleristide, Bevacizumab, Temozolomide, Pomalidomide, Niraparib, GNC-038, Pamiparib, Thalidomide and others.
  • Central Nervous System Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Central Nervous System Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Central Nervous System Tumors Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Central Nervous System Tumors Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Central Nervous System Lymphoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Drug Name: Company Name
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. F520: Shandong New Time Pharmaceutical
  11. Drug profiles in the detailed report…..
  12. Early stage products (Phase I)
  13. PRT811: Prelude Therapeutics
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. Central Nervous System Lymphoma Key Companies
  17. Central Nervous System Lymphoma Key Products
  18. Central Nervous System Lymphoma- Unmet Needs
  19. Central Nervous System Lymphoma- Market Drivers and Barriers
  20. Central Nervous System Lymphoma- Future Perspectives and Conclusion
  21. Central Nervous System Lymphoma Analyst Views
  22. Central Nervous System Lymphoma Key Companies
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/central-nervous-system-lymphoma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Central Nervous System Tumors Pipeline Appears Robust With 13+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Pediatric Brain Tumors Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Pediatric Brain Tumors Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Pediatric Brain Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Pediatric Brain Tumors Pipeline. Dive into DelveInsight’s comprehensive report today! @ Pediatric Brain Tumors Pipeline Outlook

Key Takeaways from the Pediatric Brain Tumors Pipeline Report

  • In May 2025, University of Florida announced the studies that RNA liposomes activate APCs, induce antigen-specific T cell immunity, and can supplant DCs in a cell therapy model for HGG and have shown feasibility and activity of this approach in preclinical models and in canine patients with a spontaneous malignant glioma. In one arm of this study, we will investigate the safety and immunologic activity of RNA-LP vaccines in pediatric patients with recurrent pHGG.
  • In May 2025, GlaxoSmithKline conducted a study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors. This study also aims: (a) to check if it is safe to use cobolimab and dostarlimab combination in children and young adults, (b) to see how to manage the side effects that may occur, and (c) the effect of this treatment in participants.
  • In May 2025, St. Jude Children’s Research Hospital organized studies have shown that medulloblastoma is made up of distinct molecular subgroups which respond differently to treatment. This suggests that clinical risk alone is not adequate to identify actual risk of recurrence. In order to address this, we will stratify medulloblastoma treatment in this phase II clinical trial based on both clinical risk (low, standard, intermediate, or high risk) and molecular subtype (WNT, SHH, or Non-WNT Non-SHH).
  • DelveInsight’s Pediatric Brain Tumors Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Pediatric Brain Tumors treatment.
  • Promising Pediatric Brain Tumors Companies such as Biodexa Pharmaceuticals, Cellectar Biosciences, ZIOPHARM Oncology, Y-mAbs Therapeutics Inc., Neonc Technologiesd Inc. and others.
  • The leading Pediatric Brain Tumors Pipeline Therapies such as Doxorubicin, temozolomide, thalidomide, tozuleristide, plerixafor, CX 4945, Abemaciclib and others.

Stay ahead with the most recent pipeline outlook for Pediatric Brain Tumors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pediatric Brain Tumors Treatment Drugs

Pediatric Brain Tumors Emerging Drugs Profile

  • MTX110: Biodexa Pharmaceuticals

MTX110 is a water-soluble form of panobinostat free base, achieved through complexation with hydroxypropyl-β-cyclodextrin (HPBCD) that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumor. Panobinostat is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor). The currently available oral formulation of panobinostat lactate (Farydak®) is not suitable for treatment of brain cancers owing to poor blood-brain barrier penetration and inadequate brain drug concentrations. Based on favorable translational science data, MTX110 is being evaluated clinically as a treatment for DIPG and recurrent medulloblastoma and preclinical for treatment of glioblastoma. MTX110 is delivered directly into and around the patient’s tumor via a catheter system (e.g. CED or fourth ventricle infusions) to bypass the blood-brain barrier. This technique exposes the tumor to very high drug concentrations while simultaneously minimizing systemic drug levels and the potential for toxicity and other side effects. Panobinostat has demonstrated high potency against DIPG tumor cells in in vitro and in vivo models, and in a key study it was the most promising of 83 anticancer agents tested in 14 patient-derived DIPG cell lines. Currently, the drug is in Phase I/II stage of its development for the treatment of diffuse intrinsic pontine glioma.

  • Iopofosine: Cellectar Biosciences

Iopofosine is a small-molecule Phospholipid Drug Conjugate™ designed to provide targeted delivery of iodine-131 (radioisotope) directly to cancer cells, while limiting exposure to healthy cells. Iopofosine is currently being evaluated in the CLOVER-WaM Phase II pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM), a Phase IIb study in r/r multiple myeloma (MM) patients and the CLOVER-2 Phase I study for a variety of pediatric cancers. The U.S. Food and Drug Administration granted iopofosine Fast Track Designation for WM patients having received two or more prior treatment regimens, as well as r/r MM and r/r diffuse large B-cell lymphoma (DLBCL). Orphan Drug Designations (ODDs) have been granted for WM, MM, neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma and osteosarcoma. Iopofosine was also granted Rare Pediatric Disease Designation (RPDD) for the treatment of neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma and osteosarcoma. The European Commission granted an ODDs for r/r MM and WM. Currently, the drug is in Phase I stage of its development for the treatment of pediatric brain tumor.

The Pediatric Brain Tumors Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Pediatric Brain Tumors with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pediatric Brain Tumors Treatment.
  • Pediatric Brain Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Pediatric Brain Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pediatric Brain Tumors market

Explore groundbreaking therapies and clinical trials in the Pediatric Brain Tumors Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Pediatric Brain Tumors Drugs

Pediatric Brain Tumors Companies

Biodexa Pharmaceuticals, Cellectar Biosciences, ZIOPHARM Oncology, Y-mAbs Therapeutics Inc., Neonc Technologiesd Inc. and others.

Pediatric Brain Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Pediatric Brain Tumors Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Unveil the future of Pediatric Brain Tumors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Pediatric Brain Tumors Market Drivers and Barriers

Scope of the Pediatric Brain Tumors Pipeline Report

  • Coverage- Global
  • Pediatric Brain Tumors Companies- Biodexa Pharmaceuticals, Cellectar Biosciences, ZIOPHARM Oncology, Y-mAbs Therapeutics Inc., Neonc Technologiesd Inc. and others.
  • Pediatric Brain Tumors Pipeline Therapies- Doxorubicin, temozolomide, thalidomide, tozuleristide, plerixafor, CX 4945, Abemaciclib and others.
  • Pediatric Brain Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Pediatric Brain Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Pediatric Brain Tumors Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Pediatric Brain Tumors Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Pediatric Brain Tumors: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Pediatric Brain Tumors – DelveInsight’s Analytical Perspective
  7. Drug profiles in the detailed report…..
  8. Late Stage Products (Phase III)
  9. Drug Name: Company Name
  10. Drug profiles in the detailed report…..
  11. Mid Stage Products (Phase II)
  12. Drug Name: Company Name
  13. Drug profiles in the detailed report…..
  14. Early Stage Products (Phase I/II)
  15. Comparative Analysis
  16. MTX110: Biodexa Pharmaceuticals
  17. Drug profiles in the detailed report…..
  18. Pre-clinical and Discovery Stage Products
  19. Drug Name: Company Name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Pediatric Brain Tumors Key Companies
  23. Pediatric Brain Tumors Key Products
  24. Pediatric Brain Tumors- Unmet Needs
  25. Pediatric Brain Tumors- Market Drivers and Barriers
  26. Pediatric Brain Tumors- Future Perspectives and Conclusion
  27. Pediatric Brain Tumors Analyst Views
  28. Pediatric Brain Tumors Key Companies
  29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/pediatric-brain-tumors-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pediatric Brain Tumors Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

MALT Lymphoma Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Mucosa-associated Lymphoid Tissue (MALT) Lymphoma pipeline landscape. It covers the MALT Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the MALT Lymphoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ MALT Lymphoma Pipeline Outlook

Key Takeaways from the MALT Lymphoma Pipeline Report

  • In May 2025, Incyte Corporation announced a study is to evaluate the safety and efficacy of two parsaclisib treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor.
  • In May 2025, Regeneron Pharmaceuticals announced a study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called “relapsed”), or did not respond to treatment (called “refractory”). FL and MZL are subtypes of Non-Hodgkin ‘s lymphoma (NHL).
  • In May 2025, BeiGene announced a study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.
  • DelveInsight’s MALT Lymphoma Pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for MALT Lymphoma treatment.
  • Promising MALT Lymphoma Companies such as MEI Pharma, Incyte, Genentech, BeiGene, Sound Biologics, ADC Therapeutics, Loxo Oncology and others.
  • The leading MALT Lymphoma Pipeline Therapies such as Fludarabine, Rituximab, ibrutinib, milatuzumab, veltuzumab, Cytoxan and others.

Stay ahead with the most recent pipeline outlook for MALT Lymphoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ MALT Lymphoma Treatment Drugs

MALT Lymphoma Emerging Drugs Profile

  • Tafasitamab: Incyte

Tafasitamab (MOR208) is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody directed against CD19 in clinical development for the treatment of B cell malignancies. Tafasitamab (MOR208, formerly Xmab®5574) is an investigational monoclonal antibody directed against the antigen CD19 which is broadly expressed on the surface of B cells. It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas like follicular lymphoma (FL) and marginal zone lymphomas (MZL), as well as chronic lymphocytic leukemia (CLL). Tafasitamab (MOR208) binds to CD19. This antigen is broadly and homogeneously expressed across different B cell malignancies including diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). CD19 is able to enhance B cell receptor (BCR) signaling, which is important for B cell survival. Therefore, CD19 is considered a potential therapeutic target for drugs aimed at treating B cell-related lymphomas and leukemias. Currently the product is in Phase III stage of development for the treatment of Malt Lymphoma.

The MALT Lymphoma Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of MALT Lymphoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for MALT Lymphoma Treatment.
  • MALT Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • MALT Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the MALT Lymphoma market

Explore groundbreaking therapies and clinical trials in the MALT Lymphoma Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New MALT Lymphoma Drugs

MALT Lymphoma Companies

MEI Pharma, Incyte, Genentech, BeiGene, Sound Biologics, ADC Therapeutics, Loxo Oncology and others.

Malt Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Small Molecule
  • Gene Therapy
  • Peptide
  • Immunotherapy
  • Cell Therapy

MALT Lymphoma Products have been categorized under various Molecule types such as

  • Intravenous
  • Intradermal
  • Oral
  • Subcutaneous
  • Intramuscular

Unveil the future of MALT Lymphoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ MALT Lymphoma Market Drivers and Barriers

Scope of the MALT Lymphoma Pipeline Report

  • Coverage- Global
  • MALT Lymphoma Companies- MEI Pharma, Incyte, Genentech, BeiGene, Sound Biologics, ADC Therapeutics, Loxo Oncology and others.
  • MALT Lymphoma Pipeline Therapies- Fludarabine, Rituximab, ibrutinib, milatuzumab, veltuzumab, Cytoxan and others.
  • MALT Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • MALT Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on MALT Lymphoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ MALT Lymphoma Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Malt Lymphoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Malt Lymphoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Tafasitamab: Incyte
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Mosunetuzumab: Genentech
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. BGB-10188: BeiGene
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. PSB202: Sound Biologics
  18. Drug profiles in the detailed report…..
  19. Preclinical and Discovery Stage Products
  20. Drug name: Company name
  21. Drug profiles in the detailed report…..
  22. Inactive Products
  23. Malt Lymphoma Key Companies
  24. Malt Lymphoma Key Products
  25. Malt Lymphoma – Unmet Needs
  26. Malt Lymphoma – Market Drivers and Barriers
  27. Malt Lymphoma – Future Perspectives and Conclusion
  28. Malt Lymphoma Analyst Views
  29. Malt Lymphoma Key Companies
  30. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/malt-lymphoma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: MALT Lymphoma Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight